X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the development and commercialization of cladribine. It involves targeting the cells of the adaptive immune system on treating multiple sclerosis.
Lead Product(s): Cladribine
Therapeutic Area: Neurology Product Name: Cladribine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 19, 2024
Details:
The Company intends to use the net proceeds research, development, and commercialization programs, including its proprietary ODF Cladribine dosage form, directed at the multiple sclerosis.
Lead Product(s): Cladribine
Therapeutic Area: Neurology Product Name: Cladribine-Generic
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 25, 2024
Details:
Cladribine, an oral dissolvable film product, is incorporated into DNA strands where it inhibits DNA synthesis and repair, it is being developed for the treatment of Multiple Sclerosis.
Lead Product(s): Cladribine
Therapeutic Area: Neurology Product Name: Cladribine-Generic
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
Cladribine-Generic is a ribonucleoside-diphosphate reductase inhibitor. Its orodispersible film is being evaluated in precinical studies for the treatment of Multiple Sclerosis.
Lead Product(s): Cladribine
Therapeutic Area: Neurology Product Name: Cladribine-Generic
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2024
Details:
Cladribine-Generic is a ribonucleoside-diphosphate reductase inhibitor. Its orodispersible film is being evaluated in precinical studies for the treatment of Multiple Sclerosis.
Lead Product(s): Cladribine
Therapeutic Area: Neurology Product Name: Cladribine-Generic
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
The net proceeds will be used for the development and commercialization of cladribine. It involves targeting the cells of the adaptive immune system with minimal impact on innate immune cells for the treatment of multiple sclerosis (MS).
Lead Product(s): Cladribine
Therapeutic Area: Neurology Product Name: Cladribine-Generic
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 29, 2024
Details:
Cladribine based oral dissolvable drug film (ODF) reformulation is being evaluated for the treatment of Multiple Sclerosis (MS). Preclinical work is underway with comparative pharmacokinetic and local toxicity studies in animal models having already commenced in Europe.
Lead Product(s): Cladribine
Therapeutic Area: Neurology Product Name: Cladribine-Generic
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
Under the agreement, BioNxt acquires intellectual property rights and joint development of an oral dissolvable drug reformulation using the active pharmaceutical ingredient Cladribine.
Lead Product(s): Cladribine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 13, 2023
Details:
The Company intends to use the net proceeds from the Offering, including the Final Tranche, to fund its research, development, and commercialization activities for Rotigotine and for general working capital purposes.
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 27, 2023
Details:
The Company intends to use the net proceeds to fund its research, development, and commercialization activities of its drug canditates, including Rotigotine, a non-ergoline dopamine agonist approved for the treatment of Parkinson's disease and restless legs syndrome.
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $3.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 28, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
